Drug intelligence / Profile preview

QHRD102

Development stage: Unknown
Lead developer: Jiangsu Zhonghong Bioengineering Pharmaceutical Research Institute
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular

Overview

QHRD102 is an investigational anti-CD27 monoclonal antibody developed as a novel immunotherapeutic agent. It functions as a CD27 inhibitor and is being studied for its potential to treat hematological malignancies, specifically relapsed or refractory acute lymphoblastic leukemia (ALL) and extranodal NK/T-cell lymphoma (ENKTL). The drug is administered via intramuscular injection. Clinical trials are ongoing in China to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy in these patient populations[1][4].

Targets

CD27 (Cluster of Differentiation 27)

Beyond the preview

Go deeper on QHRD102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QHRD102.

Explore the full profile